Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04056247 | Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments(PROPHETIC) | active not recruiting | — | 10,000 | OncoHost Ltd.INDUSTRY | 5 | Oct 15, 2025 | clinicaltrials |
| NCT04139902 | Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma | active not recruiting | Phase 2 | 48 | Diwakar DavarOTHER | 1 |
| Oct 15, 2025 |
| clinicaltrials |
| NCT05598853 | Intrathecal Double Checkpoint Inhibition(IT-IO) | active not recruiting | Phase 1 | 26 | University of ZurichOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06540391 | A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients(MELODY-1) | active not recruiting | Phase 1 | 41 | Microbiotica LtdINDUSTRY | 4 | Sep 26, 2025 | clinicaltrials |
| NCT05933577 | A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) | active not recruiting | Phase 3 | 1,089 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 24, 2025 | clinicaltrials |
| NCT05309421 | A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma | active not recruiting | Phase 2 | 17 | Evaxion Biotech A/SINDUSTRY | 2 | Sep 22, 2025 | clinicaltrials |
| NCT05653882 | A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | active not recruiting | Phase 1 | 552 | Asher Biotherapeutics, Inc.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT03470922 | A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma(RELATIVITY-047) | active not recruiting | Phase 2 / Phase 3 | 714 | Bristol-Myers SquibbINDUSTRY | 25 | Sep 9, 2025 | clinicaltrials |
| NCT04283890 | PHP and Immunotherapy in Metastasized UM(CHOPIN) | active not recruiting | Phase 1 / Phase 2 | 83 | Leiden University Medical CenterOTHER | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06551064 | Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients(Dahlia) | active not recruiting | Phase 1 | 96 | Formycon AGINDUSTRY | 11 | Sep 4, 2025 | clinicaltrials |
| NCT05585320 | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 209 | Immuneering CorporationINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05155254 | IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) | active not recruiting | Phase 3 | 407 | IO BiotechINDUSTRY | 16 | Aug 28, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT03611868 | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 230 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT05222932 | Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1(AVENTIL) | active not recruiting | Phase 1 | 15 | TILT Biotherapeutics Ltd.INDUSTRY | 2 | Aug 7, 2025 | clinicaltrials |
| NCT03235245 | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib(EBIN) | active not recruiting | Phase 2 | 271 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Aug 1, 2025 | clinicaltrials |
| NCT05061134 | A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition(MONETTE) | active not recruiting | Phase 2 | 194 | AstraZenecaINDUSTRY | 11 | Jul 31, 2025 | clinicaltrials |
| NCT05315258 | Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma(TebeMRD) | active not recruiting | Phase 2 | 850 | University of OxfordOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05751928 | A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma(NEO-MIMAJOR) | active not recruiting | Phase 3 | 411 | BiocadINDUSTRY | 2 | Jul 8, 2025 | clinicaltrials |
| NCT06112808 | A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin | active not recruiting | Phase 1 | 300 | BiocadINDUSTRY | 2 | Jul 8, 2025 | clinicaltrials |
| NCT06640530 | Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin(UNIVERSE) | active not recruiting | Phase 3 | 392 | BiocadINDUSTRY | 3 | Jul 8, 2025 | clinicaltrials |
| NCT05286294 | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders(MITRIC) | active not recruiting | Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT05180799 | A Phase 1/2 Study of BA3071 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 320 | BioAtla, Inc.INDUSTRY | 2 | Jun 15, 2025 | clinicaltrials |
| NCT02743819 | Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma | active not recruiting | Phase 2 | 70 | University of ChicagoOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT05592639 | VideoEndoscopic Radical Inguinal Lymphadenectomy for Penile Cancer(VELRAD) | active not recruiting | N/A | 50 | University College, LondonOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT04385732 | Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients(IMAGE) | active not recruiting | N/A | 670 | Melanoma and Skin Cancer Trials LimitedOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT03719131 | Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy | active not recruiting | Phase 2 | 15 | Emory UniversityOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
| NCT06014619 | Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs | active not recruiting | — | 500 | Maastricht University Medical CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT03772899 | Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic) | active not recruiting | Phase 1 | 20 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05736523 | Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA) | active not recruiting | — | 28 | University of UtahOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06863870 | Assessment of Circulating Tumor Cells and microRNAs in Patients With Metastatic Non-cutaneous Melanoma | active not recruiting | — | 35 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT05732805 | A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma(OCTAVA) | active not recruiting | Phase 3 | 270 | BiocadINDUSTRY | 3 | Feb 27, 2025 | clinicaltrials |
| NCT03757689 | Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma | active not recruiting | Phase 2 | 63 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06809491 | One-year Recurrence-free Survival of Melanoma Patients Eligible for a Sentinel Lymph Node Biopsy(MELASENTI) | active not recruiting | — | 200 | Central Hospital, Nancy, FranceOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT04565769 | Cognitive Function in Melanoma Patients Treated With Adjuvant Immune Checkpoint Inhibitors | active not recruiting | — | 100 | Aarhus University HospitalOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT03553836 | Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) | active not recruiting | Phase 3 | 976 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Nov 29, 2024 | clinicaltrials |
| NCT02385214 | MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma(MelMarT) | active not recruiting | N/A | 400 | Melanoma and Skin Cancer Trials LimitedOTHER | 5 | Nov 27, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT02938299 | Neoadjuvant L19IL2/L19TNF- Pivotal Study(Pivotal) | active not recruiting | Phase 3 | 214 | Philogen S.p.A.INDUSTRY | 4 | Sep 19, 2024 | clinicaltrials |
| NCT04205227 | ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 137 | ENB Therapeutics, IncINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT04309409 | Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma(NivoMela) | active not recruiting | Phase 3 | 374 | University Hospital, EssenOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT04949113 | Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma(NADINA) | active not recruiting | Phase 3 | 423 | The Netherlands Cancer InstituteOTHER | 3 | Mar 8, 2024 | clinicaltrials |
| NCT05022901 | An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma | active not recruiting | Phase 3 | 30 | Delcath Systems Inc.INDUSTRY | 1 | Dec 21, 2023 | clinicaltrials |
| NCT01942603 | Minimal SN Tumor Burden(Minitub) | active not recruiting | — | 296 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Nov 28, 2023 | clinicaltrials |
| NCT05270044 | Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.(COLUMBUS-AD) | active not recruiting | Phase 3 | 815 | Pierre Fabre MedicamentINDUSTRY | 23 | Nov 22, 2023 | clinicaltrials |
| NCT02068196 | A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.(Ipi4) | active not recruiting | Phase 4 | 150 | Oslo University HospitalOTHER | 1 | Mar 24, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Oct 15, 2025source: clinicaltrials